Your Input: | |||||
BNIP3 | Uncharacterized protein. (235 aa) | ||||
BIK | BCL2 interacting killer. (152 aa) | ||||
PPIF | Peptidyl-prolyl cis-trans isomerase; PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides; Belongs to the cyclophilin-type PPIase family. (207 aa) | ||||
TRIAP1 | Uncharacterized protein. (76 aa) | ||||
BMF | Bcl2 modifying factor. (184 aa) | ||||
MMP9 | Matrix metallopeptidase 9. (709 aa) | ||||
GHITM | Growth hormone inducible transmembrane protein; Belongs to the BI1 family. (336 aa) | ||||
FXN | Frataxin. (211 aa) | ||||
PLA2G6 | Phospholipase A2 group VI. (807 aa) | ||||
BAK1 | BCL2 antagonist/killer 1. (211 aa) | ||||
ENSPCOP00000003708 | Uncharacterized protein. (135 aa) | ||||
PARL | Rhomboid domain-containing protein. (362 aa) | ||||
CLU | Clusterin; Functions as extracellular chaperone that prevents aggregation of non native proteins. Prevents stress-induced aggregation of blood plasma proteins. (450 aa) | ||||
CIDEB | Cell death inducing DFFA like effector b. (219 aa) | ||||
PMAIP1 | Uncharacterized protein. (54 aa) | ||||
NOL3 | Nucleolar protein 3. (204 aa) | ||||
PSMD10 | Proteasome 26S subunit, non-ATPase 10. (226 aa) | ||||
PRKN | E3 ubiquitin-protein ligase parkin; Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins; Belongs to the RBR family. Parkin subfamily. (460 aa) | ||||
BBC3 | BCL2 binding component 3. (260 aa) | ||||
PLSCR3 | Phospholipid scramblase; May mediate accelerated ATP-independent bidirectional transbilayer migration of phospholipids upon binding calcium ions that results in a loss of phospholipid asymmetry in the plasma membrane. Belongs to the phospholipid scramblase family. (295 aa) | ||||
OPA1 | OPA1 mitochondrial dynamin like GTPase; Belongs to the TRAFAC class dynamin-like GTPase superfamily. Dynamin/Fzo/YdjA family. (997 aa) | ||||
HGF | Hepatocyte growth factor; Potent mitogen for mature parenchymal hepatocyte cells, seems to be a hepatotrophic factor, and acts as a growth factor for a broad spectrum of tissues and cell types. Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerization. Belongs to the peptidase S1 family. Plasminogen subfamily. (703 aa) | ||||
IGF1 | Insulin like growth factor 1. (208 aa) | ||||
AVP | Arginine vasopressin. (116 aa) | ||||
BAX | BCL2 associated X, apoptosis regulator. (199 aa) | ||||
PRELID1 | PRELI domain containing 1. (219 aa) | ||||
BCL2L1 | BCL2 like 1. (233 aa) | ||||
DNM1L | Dynamin 1 like; Belongs to the TRAFAC class dynamin-like GTPase superfamily. Dynamin/Fzo/YdjA family. (749 aa) | ||||
ENSPCOP00000021800 | Uncharacterized protein. (175 aa) | ||||
TNFSF10 | Tumor necrosis factor ligand superfamily member. (288 aa) | ||||
FAM162A | Family with sequence similarity 162 member A. (155 aa) | ||||
ENSPCOP00000024369 | Uncharacterized protein; Belongs to the intermediate filament family. (156 aa) | ||||
BCL2L11 | BCL2 like 11. (200 aa) | ||||
PINK1 | PTEN induced kinase 1. (581 aa) | ||||
HRK | Harakiri, BCL2 interacting protein. (91 aa) | ||||
AKT1 | Non-specific serine/threonine protein kinase; Belongs to the protein kinase superfamily. (480 aa) | ||||
BAD | BCL2 associated agonist of cell death. (168 aa) | ||||
LMNA | Lamin A/C; Belongs to the intermediate filament family. (665 aa) | ||||
PYCARD | PYD and CARD domain containing. (195 aa) | ||||
TP53 | Cellular tumor antigen p53; Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression; Belongs to the p53 family. (385 aa) | ||||
BID | BH3-interacting domain death agonist; Counters the protective effect of Bcl-2. (220 aa) |